# Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

> **NCT00064636** · PHASE1 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 46 (—)

## Conditions studied

- Advanced Non-Small Cell Lung Cancer
- Other Solid Tumors

## Interventions

- **DRUG:** VELCADE TM (bortezomib) for Injection, or PS-341

## Key facts

- **NCT ID:** NCT00064636
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 46 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00064636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00064636, "Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00064636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*